Multiple Sclerosis Research Repository

1. “Refuseniks-2” by Dr. Gavin Giovannoni (3-4-2022)

-”I am beginning to refer to my colleagues who are not prepared to offer and use alemtuzumab and HSCT as the ‘refuseniks.’

-”In reality, it is not the neurologist or the institution the neurologist works with who is taking a risk when someone is treated with alemtuzumab, but it is the patient who is taking the risk.  Don’t they understand this?”